Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 12/20 | 0.68 |
| ▸ | ADORA2B | P29275 | 8/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | NT5E | P21589 | 1/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13437799 | 1.00 | ADORA2A (0.68) | ADORA2AADORA2BADORA3ADORA1LMNA | |
| SCHEMBL13403870 | 1.00 | ADORA2A (0.68) | ADORA2AADORA2BADORA3ADORA1LMNA | |
| SCHEMBL3423089 | 0.82 | ADORA2A (0.68) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL2774718 | 0.82 | LMNA (0.72) | ADORA2AADORA2BADORA3ADORA1LMNA | |
| SCHEMBL272005 | 0.82 | ADORA2A (0.78) | ADORA2ALMNANT5EHIF1A | |
| SCHEMBL13437722 | 0.82 | ADORA2A (0.78) | ADORA2ALMNANT5EHIF1A | |
| SCHEMBL13403866 | 0.82 | ADORA2A (0.78) | ADORA2ALMNANT5EHIF1A | |
| SCHEMBL7027258 | 0.81 | LMNA (0.64) | ADORA2AADORA2BADORA3ADORA1LMNA | |
| SCHEMBL4349253 | 0.81 | LMNA (0.70) | ADORA2AADORA2BADORA3ADORA1LMNA | |
| SCHEMBL7027272 | 0.81 | LMNA (0.64) | ADORA2AADORA2BADORA3ADORA1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1192169-B1 | C-PYRAZOLE A2A RECEPTOR AGONISTS | CV THERAPEUTICS INC (US) | 2003-05-14 | — | — | EP | claimed |
| US-20010018428-A1 | C-pyrazole A2A receptor agonists | CV THERAPEUTICS, INC. | 2001-08-30 | — | — | US | claimed |
| US-6214807-B1 | IMAGES AND CARDIOVASCULAR DISORDERS | CV THERAPEUTICS, INC. | 2001-04-10 | — | — | US | claimed |
| US-9289446-B2 | Myocardial perfusion imaging methods and compositions | GILEAD SCIENCES, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150283162-A1 | MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS | GILEAD PALO ALTO, INC. | 2015-10-08 | — | — | US | disclosed |
| US-8906878-B2 | Myocardial perfusion imaging methods and compositions | GILEAD SCIENCES, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20130343987-A1 | MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS | GILEAD SCIENCES, INC. (US) | 2013-12-26 | — | — | US | disclosed |
| EP-1708721-B1 | MYOCARDIAL PERFUSION IMAGING USING ADENOSINE RECEPTOR AGONISTS | GILEAD SCIENCES INC (US) | 2013-08-07 | — | — | EP | disclosed |
| EP-2366396-B1 | Myocardial perfusion imaging using adenosine receptor agonists | GILEAD SCIENCES INC (US) | 2013-08-07 | — | — | EP | disclosed |
| US-8470801-B2 | Myocardial perfusion imaging methods and compositions | GILEAD SCIENCES, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| EP-2056834-B1 | METHODS AND COMPOSITIONS FOR INCREASING PATIENT TOLERABILITY DURING MYOCARDIAL IMAGING METHODS | GILEAD SCIENCES INC (US) | 2012-08-29 | — | — | EP | disclosed |
| US-20040198692-A1 | C-pyrazole A2A receptor agonists | CV THERAPEUTICS, INC. | 2004-10-07 | — | — | US | disclosed |
| US-6770634-B1 | STIMULATE MAMMALIAN CORONARY VASODILATATION FOR THERAPEUTIC PURPOSES AND IMAGING THE HEART | CV THERAPEUTICS, INC. | 2004-08-03 | — | — | US | disclosed |
| US-20040064039-A1 | Myocardial perfusion imaging method | CV THERAPEUTICS | 2004-04-01 | — | — | US | disclosed |
| WO-2004011010-A1 | MYOCARDIAL PERFUSION IMAGING USING A2A RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2004-02-05 | — | — | WO | disclosed |
| EP-1192169-B1 | C-PYRAZOLE A2A RECEPTOR AGONISTS | CV THERAPEUTICS INC (US) | 2003-05-14 | — | — | EP | disclosed |
| EP-1192169-A2 | C-PYRAZOLE A2A RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2002-04-03 | — | — | EP | disclosed |
| US-20010018428-A1 | C-pyrazole A2A receptor agonists | CV THERAPEUTICS, INC. | 2001-08-30 | — | — | US | disclosed |
| US-6214807-B1 | IMAGES AND CARDIOVASCULAR DISORDERS | CV THERAPEUTICS, INC. | 2001-04-10 | — | — | US | disclosed |
| WO-2000078778-A2 | C-PYRAZOLE A2A RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2000-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150283162-A1 | MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA2B 4/4885ADORA3 2/4885 |
| US-20040198692-A1 | C-pyrazole A2A receptor agonists | ADORA2A, ADORA3, TBXA2R | ADORA2A 1/4885ADORA2B 5/4885ADORA3 2/4885 |
| US-20010018428-A1 | C-pyrazole A2A receptor agonists | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA2B 6/4885ADORA3 2/4885 |
| US-20130343987-A1 | MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA2B 4/4885ADORA3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.